# Dr. Donald Kohn has been developing gene therapies for rare pediatric immune disorders for over 30 years.

*biotech · news · 2026-03-28 · Medical Xpress*

## Key points

- Kresladi is the first FDA-approved gene therapy for severe leukocyte adhesion deficiency-I in the U.S.
- All nine clinical trial patients survived without bone marrow transplant or immune rejection after Kresladi treatment.
- Kresladi uses patients' own stem cells with a healthy ITGB2 gene, reducing toxicity and immune complications.
- This FDA approval is the first ever for a CIRM-supported gene therapy, marking a major milestone.
- Long-term follow-up is required to confirm Kresladi's clinical benefit through a post-marketing registry.

**Companies:** Rocket Pharmaceuticals
**Countries:** United States, United Kingdom, Spain

[Read the full story on Medical Xpress](https://medicalxpress.com/news/2026-03-fda-gene-therapy-severe-leukocyte.html)

---

Canonical: https://newsio.io/n/e7aecb98-4fd2-4323-aa4a-3fcebffb5a74/dr-donald-kohn-has-been-developing-gene-therapies-for-rare-pediatric-immune-diso
Summarized by Newsio from Medical Xpress. https://newsio.io/how-it-works